Cholera Toxin Analysis to Vaccine Design
The cholera toxin (CT) from Vibrio cholerae is responsible for the clinical symptoms of cholera. CT is a hetero-hexamer (AB5) protein complex consisting of a CTA subunit with a pentamer (B5) of CTB. The AB5 hexamer complex is associated with the pathogenesis of the disease. Therefore, it is of interest to study the structure of CT analyzing the nature of interfaces between CTA and CTB to characterize mutations in known serogroups. The importance of mutations in these interfaces among known serogroups is relevant in the design of an effective vaccine candidate for cholera.
KeywordsCholera toxin (CT) Vibrio cholerae O1/O139 Non O1/O139 Mutation Protein-protein interfaces
- Domenighini M et al. (2000) Immunogenic detoxified mutants of cholera toxin and of the toxin LT, their preparation and their use for the preparation of vaccines. US Patent 6,149,919Google Scholar
- Finkelstein RA. Owen P, Foster TS (1988) Cholera, the cholera enterotoxins, and the cholera enterotoxin-related enterotoxin family. Immuno-chemical and molecular genetic analysis of bacterial pathogens. p 85–102Google Scholar
- Green BA et al. (2008) Wyeth Holdings Corporation and The Regents of the University of Colorado, assignee. Mutant forms of cholera holotoxin as an adjuvant. US Patent 7,361,355Google Scholar
- Pizza M et al. (2009) Novartis vaccines and diagnostics SRL, assignee. Immunogenic detoxified mutants of cholera toxin. US Patent 7,632,513Google Scholar
- Raychoudhuri A et al (2009) Classical ctxB in Vibrio cholerae O1, Kolkata, India. Emerg Infect Dis 15(1):131–132. https://doi.org/10.3201/eid1501.080543